Vizsgálati helyszín
Hospital Quironsalud Sagrado Corazon
Sevilla, 41013, SpanyolországMég nincs intézményhez kötve
- 19futó vizsgálat
- 15lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 34 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis21 vizsgálat
- 2. fázis12 vizsgálat
- 4. fázis1 vizsgálat
- Állapot
- Lezárult15 vizsgálat
- Fut, nem toboroz11 vizsgálat
- Toboroz7 vizsgálat
- Még nem toboroz1 vizsgálat
- Fő szponzor
- Janssen Research & Development, LLC4 vizsgálat
- MedSIR4 vizsgálat
- Sun Pharmaceutical Industries Limited3 vizsgálat
- AstraZeneca2 vizsgálat
- MoonLake Immunotherapeutics AG2 vizsgálat
- és még 17
Futó vizsgálatok
Toboroz
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058· 3. fázis· Takeda· Forrás
Még nem toboroz
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Toboroz
RANDOMISED, MULTICENTRE, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MONTELUKAST VS. PLACEBO IN PATIENTS WITH EROSIVE/INFLAMMATORY OSTEOARTHRITIS OF THE HANDS. MOTHER Study.
2025-521802-17-00· 3. fázis· Farmalider S.A.· Forrás
Toboroz
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
NCT06486883· 2. fázis· MedSIR· Forrás
Fut, nem toboroz
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
2024-516213-20-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Toboroz
A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy
2023-507097-41-01· 3. fázis· Shanghai Junshi Biosciences Co. Ltd.· Forrás
Fut, nem toboroz
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496· 3. fázis· Takeda· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
NCT06382948· 3. fázis· MedSIR· Forrás
Fut, nem toboroz
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
NCT06172127· 2. fázis· MedSIR· Forrás
Fut, nem toboroz
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
NCT05672576· 3. fázis· Viatris Innovation GmbH· Forrás
Toboroz
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654· 3. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
NCT04991116· 3. fázis· Sun Pharmaceutical Industries Limited· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
NCT05353257· 3. fázis· Shanghai Henlius Biotech· Forrás
Fut, nem toboroz
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210· 4. fázis· Janssen Research & Development, LLC· Forrás
Meghívásos bevonás
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
NCT04976322· 3. fázis· UCB Biopharma SRL· Forrás
Fut, nem toboroz
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
NCT04882098· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.
NCT04053322· 2. fázis· UNICANCER· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis
NCT07225829· 2. fázis· 4Moving Biotech· Forrás
Fut, nem toboroz
Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC
NCT06219317· 2. fázis· European Organisation for Research and Treatment of Cancer - EORTC· Forrás
Lezárult
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome
NCT06312020· 2. fázis· Horizon Therapeutics Ireland Designated Activity Company· Forrás
Lezárult
HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease
NCT05865990· 2. fázis· MedSIR· Forrás
Lezárult
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
NCT05586971· 3. fázis· LG Chem· Forrás
Lezárult
The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)
NCT05162586· 2. fázis· EMD Serono Research & Development Institute, Inc.· Forrás
Lezárult
Advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer
NCT05207709· 3. fázis· Solti Group· Forrás
Lezárult
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Subjects with Active Psoriatic Arthritis II (INSPIRE 2)
2024-512142-42-00· 3. fázis· Sun Pharmaceutical Industries Limited· Forrás
Lezárult
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
NCT04936308· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
NCT04736173· 2. fázis· Arcus Biosciences, Inc.· Forrás
Lezárult
Clinical Trial to evaluate the efficacy of immunotherapy in a subset of Hormonal Receptor-positive/HER2-negative advanced breast cancer
patients who have progressed to standard therapy.
2023-508546-17-00· 2. fázis· Solti Group· Forrás
Lezárult
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
NCT04314544· 3. fázis· Sun Pharmaceutical Industries Limited· Forrás
Fut, nem toboroz
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
NCT04305496· 3. fázis· AstraZeneca· Forrás
Lezárult
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT03563716· 2. fázis· Genentech, Inc.· Forrás
Lezárult
Clinical trial to compare the efficacy and tolerability of fulvestrant (FaslodexTM) 500mg with placebo versus fulvestrant (FaslodexTM) 500mg with PD-0332991 (Palbociclib), randomly assigned, as first line treatment for postmenopausal women with hormone receptor-positive metastatic breast cancer, who have completed at least 5 years of hormonal therapy and remained disease free for more than 12 months following its completion or who have metastatic disease diagnosed from the beginning.
2024-516132-10-00· 2. fázis· Fundacion Grupo Espanol De Investigacion En Cancer De Mama· Forrás
Hibát jelzek